home / stock / imcr / imcr articles
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combinat...
H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating on Immunocore Holdings Plc (NASDAQ: IMCR) with a price targ...
Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results ...
Needham has initiated coverage on Immunocore Holdings Plc (NASDAQ: IMCR) with a Buy rating and a price target of $75. Needham a...
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 September 2023...
News, Short Squeeze, Breakout and More Instantly...
Immunocore Holdings plc Company Name:
IMCR Stock Symbol:
NASDAQ Market:
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn...
2024-04-22 10:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...